Advanced search
Publication Cover
Leukemia & Lymphoma Volume 62, 2021 - Issue 9
Submit an article Journal homepage
369
Views
1
CrossRef citations to date
0
Altmetric
Letters to the Editor

Selection process and causes of non-eligibility for CD19 CAR-T cell therapy in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma in a European center

Cecilia Carpioa Department of Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital (HUVH), Universitat Autònoma de Barcelona, Barcelona, Spain;b Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, SpainORCID Iconhttps://orcid.org/0000-0001-9346-0134
ORCID Icon,
Gloria Iacobonia Department of Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital (HUVH), Universitat Autònoma de Barcelona, Barcelona, Spain;b Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain
,
Guillermo Villacampac Oncology Data Science (OdysSey) Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, SpainORCID Iconhttps://orcid.org/0000-0003-4868-6585
ORCID Icon,
Eva Cataláa Department of Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital (HUVH), Universitat Autònoma de Barcelona, Barcelona, Spain;b Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain
,
Sabela Bobilloa Department of Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital (HUVH), Universitat Autònoma de Barcelona, Barcelona, Spain;b Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain
,
Ana Péreza Department of Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital (HUVH), Universitat Autònoma de Barcelona, Barcelona, Spain;b Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain
,
Moraima Jiméneza Department of Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital (HUVH), Universitat Autònoma de Barcelona, Barcelona, Spain;b Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain
,
Laura Seguraa Department of Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital (HUVH), Universitat Autònoma de Barcelona, Barcelona, Spain;b Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain
,
Mireia Olivéa Department of Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital (HUVH), Universitat Autònoma de Barcelona, Barcelona, Spain;b Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain
,
Anna Farriolsa Department of Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital (HUVH), Universitat Autònoma de Barcelona, Barcelona, Spain;b Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain
,
Pau Abrisquetaa Department of Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital (HUVH), Universitat Autònoma de Barcelona, Barcelona, Spain;b Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain
,
David Valcárcela Department of Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital (HUVH), Universitat Autònoma de Barcelona, Barcelona, Spain;b Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, SpainORCID Iconhttps://orcid.org/0000-0002-8747-078X
ORCID Icon,
María Josep Carrerasa Department of Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital (HUVH), Universitat Autònoma de Barcelona, Barcelona, Spain;b Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain
,
Francesc Boscha Department of Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital (HUVH), Universitat Autònoma de Barcelona, Barcelona, Spain;b Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, SpainORCID Iconhttps://orcid.org/0000-0001-9241-2886
ORCID Icon &
Pere Barbaa Department of Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital (HUVH), Universitat Autònoma de Barcelona, Barcelona, Spain;b Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, SpainCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-7076-7969
ORCID Icon show all
Pages 2288-2291 | Received 21 Sep 2020, Accepted 27 Mar 2021, Published online: 24 Apr 2021

References

  • Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800–1808.
  • Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-Cell lymphoma. N Engl J Med. 2017;377(26):2531–2544.
  • Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45–56.
  • Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial. Lancet Oncol. 2019;20(1):31–42.
  • Perica K, Curran KJ, Brentjens RJ, et al. Building a CAR garage: preparing for the delivery of commercial CAR T cell products at Memorial Sloan Kettering Cancer Center. Biol Blood Marrow Transplant. 2018;24(6):1135–1141.
  • Jain T, Bar M, Kansagra AJ, et al. Use of chimeric antigen receptor T cell therapy in clinical practice for relapsed/refractory aggressive B cell non-Hodgkin lymphoma: an expert panel opinion from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant. 2019;25(12):2305–2321.
  • Bachanova V, Bishop MR, Dahi P, et al. Chimeric antigen receptor T cell therapy during the COVID-19 pandemic. Biol Blood Marrow Transplant. 2020;26(7):1239–1243.
  • Nastoupil LJ, Jain MD, Feng L, et al. Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium. J Clin Oncol. 2020;38(27):3119–3128.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.